Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Darzalex Faspro (daratumumab and hyaluronidase-fihj)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Genmab, Halozyme, J&J

Drug class:

CD38 inhibitor

Related drugs:

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval daratumumab and hyaluronidase-fihj Sensitive : A1	daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	thalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval thalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	thalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval thalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	pomalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval pomalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	pomalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval pomalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1